Alexion Pharmaceuticals (ALXN) was Downgraded to a Hold Rating at William Blair
In a report released today, Raju Prasad from William Blair downgraded Alexion Pharmaceuticals (ALXN) to Hold. The company’s shares closed last Thursday at $104.81.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 17.2% and a 57.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Alexion Pharmaceuticals is a Strong Buy with an average price target of $147.63, representing a 40.3% upside. In a report released today, Oppenheimer also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
Based on Alexion Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.44 billion and net profit of $558 million. In comparison, last year the company earned revenue of $1.14 billion and had a net profit of $588 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.